Evidence map›Paper›PMID 25575527›Full record

ArticleStem cells translational medicine2015

Putative immunogenicity expression profiling using human pluripotent stem cells and derivatives.

Jason P Awe, Eric H Gschweng, Agustin Vega-Crespo, Jon Voutila, Mary H Williamson, Brian Truong, Donald B Kohn, Noriyuki Kasahara, James A Byrne

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Modeling Lewy body disease withScience advances · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jason P AweDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Eric H GschwengDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Agustin Vega-CrespoDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Jon VoutilaDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Mary H WilliamsonDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Brian TruongDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Donald B KohnDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Noriyuki KasaharaDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
James A ByrneDepartment of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA jbyrne@mednet.ucla.edu.
University of California, Los Angeles · USBroad Center · USMattel Children's Hospital · US

Funding

UCLA MSD ProgramR25GM055052 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BARBER, PAUL HENRY, HASSON, TAMA W. · 1996 to 2021
$9.2M
6 · The paper itself

Abstract

Autologous human induced pluripotent stem cells (hiPSCs) should allow cellular therapeutics without an associated immune response. This concept has been controversial since the original report that syngeneic mouse iPSCs elicited an immune response after transplantation. However, an investigative analysis of any potential acute immune responses in hiPSCs and their derivatives has yet to be conducted. In the present study, we used correlative gene expression analysis of two putative mouse "immunogenicity" genes, ZG16 and HORMAD1, to assay their human homologous expression levels in human pluripotent stem cells and their derivatives. We found that ZG16 expression is heterogeneous across multiple human embryonic stem cell and hiPSC-derived cell types. Additionally, ectopic expression of ZG16 in antigen-presenting cells is insufficient to trigger a detectable response in a peripheral blood mononuclear cell coculture assay. Neither of the previous immunogenicity-associated genes in the mouse currently appears to be relevant in a human context.

Indexed as

Gene Expression ProfilingAnimalsCell LineEmbryonic Stem CellsGene Expression RegulationHumansLectinsMembrane ProteinsMicePluripotent Stem CellsSpecies SpecificityLectinsMembrane ProteinsZG16 protein, humanZG-16 protein, mouseHORMAD1Human embryonic stem cellHuman induced pluripotent stem cellImmunogenicityPeripheral blood mononuclear cellsZG16

Identifiers

PMID25575527
PMCPMC4303355
OpenAlexW1970221511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.